Earth News from TerraDaily.com
Press Release from Business Wire: Onego Bio
(AFP) Feb 04, 2026
HELSINKI, Feb 4, 2026 (BSW) - Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/

Dr. Antti Vasara


Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe's foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy-including impactful work with Nokia and strategic contributions to European research and development initiatives.

"Antti is one of the most respected leaders in science and innovation," said Maija Itkonen, CEO of Onego Bio. "His deep understanding of technology commercialization and ecosystem level strategy will be invaluable as Onego accelerates its mission to deliver resilient, sustainable ingredients at scale."

Dr. Vasara joins Onego Bio at a pivotal moment, as the company advances commercialization of Bioalbumen(R), its non-animal egg protein that matches the taste, nutrition, and functionality of traditional egg protein while offering supply stability and a significantly smaller environmental footprint. Bioalbumen(R) is gaining traction across food manufacturing, baking, and consumer packaged goods sectors as a reliable, non-animal ingredient solution.

"Onego Bio is not just redesigning food ingredients-it is delivering industrial?scale solutions grounded in science and built for efficiency," said Dr. Vasara. "I'm excited to contribute to a team that is solving real supply chain challenges with technology that's both scalable and globally needed."

About Onego Bio

Onego Bio is a food ingredient company on a mission to create a more resilient food system through its product Bioalbumen(R): the first non-animal egg protein with an amino acid sequence identical to the natural protein. Made through precision fermentation, Bioalbumen(R) matches the taste, nutrition, and functionality of the main protein from traditional eggs with an environmental impact around 90% smaller. Its unmatched versatility makes it ideal across a wide range of applications, while providing cost and supply stability for food manufacturers. Learn more at www.onego.bio



View source version on businesswire.com: https://www.businesswire.com/news/home/20260204881159/en/




Contact

For media inquiries contact [email protected]



© 2026 Business Wire, Inc.Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.





Space News from SpaceDaily.com
International crew arrives at space station
Vietnam licenses Musk's satellite internet firm Starlink
The Ultimate Experience at Pinco Casino - Where Quality Meets Innovation

24/7 Energy News Coverage
India plans AI 'data city' on staggering scale
All-in on AI: what TikTok creator ByteDance did next
Airlines told to cut Paris flights amid snow warnings

Military Space News, Nuclear Weapons, Missile Defense
European debate over nuclear weapons gains pace
UN nuclear watchdog chief says Iran inspection accord 'terribly difficult'
Iran says ready for nuclear compromise if US lifts sanctions

24/7 News Coverage
Russia avoids confrontation in Arctic, Norwegian official says
Eternal City eternally damp as Rome suffers record rainfall; Calabria again under water
Rome fells majestic pine trees near Colosseum


ADVERTISEMENT



All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.